Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Damon on Allogeneic Stem Cell Transplant in AML

Lloyd Damon, MD
Published: Monday, Oct 29, 2018


Lloyd Damon, MD, director of the Adult Blood and Marrow Transplant and Hematologic Malignancies Program, and chief of the University of California, San Francisco (UCSF) Hematology Clinic, UCSF Helen Diller Family Comprehensive Cancer Center, discusses allogeneic stem cell transplant (ASCT) in the treatment of patients with acute myeloid leukemia (AML).

ASCT remains the standard of care for patients with FLT3-mutated AML, says Damon, and should be done in every eligible patient. One of the unanswered questions in terms of transplant is whether a FLT3 inhibitor as maintenance after transplant is of value.

A large trial known as BMT CTN 1506/2215-CL-0304 is being conducted in this population. That trial is open to patients at UCSF, notes Damon. Patients with FLT3-mutated AML in first remission going through allogeneic transplant of any type will then be randomized to 2 years of gilteritinib, another potent and specific FLT3 inhibitor, or placebo, states Damon.

Lloyd Damon, MD, director of the Adult Blood and Marrow Transplant and Hematologic Malignancies Program, and chief of the University of California, San Francisco (UCSF) Hematology Clinic, UCSF Helen Diller Family Comprehensive Cancer Center, discusses allogeneic stem cell transplant (ASCT) in the treatment of patients with acute myeloid leukemia (AML).

ASCT remains the standard of care for patients with FLT3-mutated AML, says Damon, and should be done in every eligible patient. One of the unanswered questions in terms of transplant is whether a FLT3 inhibitor as maintenance after transplant is of value.

A large trial known as BMT CTN 1506/2215-CL-0304 is being conducted in this population. That trial is open to patients at UCSF, notes Damon. Patients with FLT3-mutated AML in first remission going through allogeneic transplant of any type will then be randomized to 2 years of gilteritinib, another potent and specific FLT3 inhibitor, or placebo, states Damon.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x